pohob, page-11

In response to zenmammon,

I would be very surprised if the deal with Nestle was simply a royalty based deal which picked up a paltry 2% - 3%. POH's IP is protected by patents and I'd be reasonably confident that they would be able to negotiate an outcome that would be far more favourable.

I have a friend who is very well qualified to comment on the clinical data achieved so far and he believes their technology is statistically very, very significant.

In my opinion this stock has the potential to be many multiples of its current price based on any one of projects they have in the pipeline succeeding.

I'm happy to hold and have accumulated a nice position over recent months with a longer term view.

Cheers
Boomer



Cheers
Boomer